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Abstract
Increasing numbers of human cowpox virus infections that are being observed and that particularly affect young non-
vaccinated persons have renewed interest in this zoonotic disease. Usually causing a self-limiting local infection, human
cowpox can in fact be fatal for immunocompromised individuals. Conventional smallpox vaccination presumably protects
an individual from infections with other Orthopoxviruses, including cowpox virus. However, available live vaccines are
causing severe adverse reactions especially in individuals with impaired immunity. Because of a decrease in protective
immunity against Orthopoxviruses and a coincident increase in the proportion of immunodeficient individuals in today’s
population, safer vaccines need to be developed. Recombinant subunit vaccines containing cross-reactive antigens are
promising candidates, which avoid the application of infectious virus. However, subunit vaccines should contain carefully
selected antigens to confer a solid cross-protection against different Orthopoxvirus species. Little is known about the cross-
reactivity of antibodies elicited to cowpox virus proteins. Here, we first identified 21 immunogenic proteins of cowpox and
vaccinia virus by serological screenings of genomic Orthopoxvirus expression libraries. Screenings were performed using
sera from vaccinated humans and animals as well as clinical sera from patients and animals with a naturally acquired
cowpox virus infection. We further analyzed the cross-reactivity of the identified immunogenic proteins. Out of 21 identified
proteins 16 were found to be cross-reactive between cowpox and vaccinia virus. The presented findings provide important
indications for the design of new-generation recombinant subunit vaccines.
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Introduction
The genus Orthopoxvirus (OPV) from the family Poxviridae contains
complex viruses which replicate entirely in the cytoplasm of the
infected cell [1,2]. Their linear double-stranded DNA genome of up
to 220 kbp[1]contains no intronsand encodes more than 200 open
reading frames (ORFs) [3]. The genus is best known for two of its
most prominent species: vaccinia virus (VACV) and variola virus
(VARV). Interestingly, VACV was used to eradicate VARV, the
causative agent of smallpox, through a worldwide vaccination
campaign [4,5]. This was possible due to an antigenic relationship
between members of OPVs. An earlier infection with one of these
members provides some protection against subsequent infections
with the others [6]. Nevertheless, the declaration of the successful
eradication of smallpox in 1980 [7] led to the discontinuation of the
routine smallpox vaccination [8] due to the risk of rare but severe
adverse reactions [9,10]. Other human-pathogenic OPV members
include monkeypox virus and cowpox virus (CPXV) [1], the latter
having the largest genome of all OPVs [11].
CPXV is prevalent in Western Eurasia and has an extremely
broad host range [4,12]. Human cowpox is a zoonotic disease,
usually transmitted by cats, which mostly causes self-limiting local
infections [13]. However, severe clinical courses resulting in
prolonged treatment and scarring have been described [13,14].
Furthermore, a case of generalized, fatal CPXV infection in an
immunocompromised patient with a life-long history of atopic
dermatitis has been reported [15]. Human cowpox particularly
affects young people [16], indicating that the lack of smallpox
vaccination may render today’s population more susceptible to
OPV infections including cowpox [17,18]. At the same time there is
no approved effective antiviral treatment available, and conven-
tional smallpox vaccines recently administered can cause rare but
severe adverse reactions [5], notably affecting immunodeficient
individuals and those with atopic dermatitis [19,20]. Unfortunately,
this group is already at a higher risk to develop OPV infections with
a severe clinical course. Therefore, there is a pressing need for the
developmentand approval ofsafer and more effectivevaccines[17].
Recombinant subunit-based vaccines represent possible alter-
natives to the conventional smallpox vaccines [21]. To develop
these vaccines, it is necessary to identify those antigens inducing
the most effective immune response. Several antigenic VACV
proteins and combinations thereof have been successfully tested in
animal models [22–24]. However, beside individual immune
responses, the genetic diversity of poxviruses has to be taken into
account when designing subunit vaccines [25]. It has long been
known that VACV and CPXV show immunological similarities as
well as differences [26–28]. However, as yet little is known about
the cross-reactive CPXV antigens. The inclusion of antigens that
are cross-reactive to several OPV species in subunit vaccines could
potentially help confer a resilient immune response [21] and
prepare more effective subunit vaccines.
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21950In this study, we first constructed and evaluated four different
genomic bacteriophage l-based expression libraries (EL) contain-
ing the VACV and CPXV genomes. The EL were then
serologically screened using sera from VACV-immunized humans
and animals as well as clinical serum samples from CPXV-infected
humans and animals. Through these screenings we were able to
identify 21 immunogenic proteins of CPXV and VACV. The
identified proteins show diverse functions and a genome-wide
distribution, with surface proteins as well as non-surface (structure)
proteins being present. By analyzing the whole set of antigens, we
found 16 out of 21 proteins to be cross-reactive between CPXV
and VACV. Six of these 16 cross-reactive proteins are also
perfectly conserved among all OPVs. Seven cross-reactive proteins
are proposed to be tested as components of subunit vaccines. We
therefore describe a low-priced approach to antigen discovery
which is especially well suited for investigation of large DNA
viruses. The approach described is independent of a prior
knowledge of antibody targets. Software-based ORF prediction
and primer design are thus not required. The method described is
therefore suitable for the identification of cross-reactive proteins
shared by further clinically relevant OPV species beside those of
VACV and CPXV. The integration of clinical serum samples in
the screening experiments in addition to sera obtained from
immunized individuals further provides a more authentic
situation, allowing the identification of the most antigenic proteins.
These proteins might be especially well suited for inclusion in
subunit vaccines.
Results
Construction and validation of genomic OPV expression
libraries
The data presented here were derived from serological
screenings of four genomic OPV EL varying in the genome
species expressed and insert size. The genomic EL were
constructed by cloning fragments of genomic OPV DNA into a
modified bacteriophage l-based vector (ZAP Express). This vector
can accommodate DNA fragments with a length of up to 12 kb.
The cloned DNA fragments can be excised out of the phage in the
form of the kanamycin-resistant pBK-CMV phagemid vector,
which allows to characterize insert DNA in a plasmid system.
Two of the EL described were constructed using partially
digested CPXV genomic DNA of strain GuWi and designated
according to insert size: EL-CPXV-0.2k-0.7k and EL-CPXV-0.2k-3k.
Additionally, two EL containing the VACV genome strain New
York City Board of Health (NYCBH) were constructed and
designated EL-VACV-3k-12k and EL-VACV-0.2k-0.7k. Exemplary,
EL-CPXV-0.2k-3k is an EL containing 0.2–3 kb inserts of a
partially digested CPXV genome. The recombinant titer of the
constructed EL ranged from 3610
6 to 2610
9 plaque forming units
per milliliter.
For the validation process recombinant plaques were randomly
picked and the insert DNA sequenced. The obtained sequences
were aligned with an appropriate OPV genome. Figure S1
schematically shows the distribution of the sequences on an OPV
genome for EL-VACV-3k-12k (A) and EL-CPXV-0.2k-0.7k (B). For
further validation of their complexity the constructed libraries
were screened with monoclonal (anti-rA27, anti-CPXV 3D11) and
polyclonal (goat anti-rA27) antibodies. First, the libraries were
screened with the monoclonal anti-CPXV 3D11 antibody. This
antibody was generated against native CPXV particles [29].
Through library screenings, immunopositive signals for the
expected antigen could be identified (Figure S2), as confirmed
by sequencing. The anti-rA27 antibodies were first tested in an
ELISA system. Here they were shown to recognize virus particles
as well as the recombinant protein expressed in E. coli that was
used to immunize goats and mice (Figure S3). Through library
screenings, positive signals for the expected antigen were identified
for all tested antibodies (Figure 1A–D), as confirmed by
sequencing.
To show the functionality of the screening system, several
controls were performed (Figure 1E–H). For the identification of
the most antigenic proteins and a maximum reduction of the
background signal all sera were diluted 1/200 to 1/1000. All
human sera were preincubated with E. coli lysate to remove anti-E.
coli antibodies that might potentially be present. Thus, after
reducing the background signal, a clear differentiation between
positive and negative signals was possible (Figure 1E). No positive
Figure 1. Validation of constructed genomic expression libraries. For a validation of their complexity the constructed genomic EL were
serologically screened with polyclonal and monoclonal antibodies of known specificities. Immunopositive signals are exemplary indicated through
white arrows for the following screening combinations: (A) EL-CPXV-0.2k-0.7k with polyclonal goat anti-rA27 serum, (B) EL-CPXV-0.2k-3k with
monoclonal mouse anti-rA27 antibody, (C) EL-VACV-3k-12k with goat anti-rA27, and (D) EL-VACV-0.2k-0.7k with goat anti-rA27. Further evaluation was
performed by immunoscreening a genomic CPXV EL with different sera and controls: (E) Immunoscreening of EL-CPXV-0.2k-3k using serum from a
VACV-immunized rabbit. The white arrow points to an immunopositive plaque, the black arrow to an immunonegative plaque. (F) Goat anti-rabbit
IgG conjugate alone without primary antibody. (G) Human serum from a poxvirus-naive person. (H) Human poxvirus-naive anti-dengue virus serum.
doi:10.1371/journal.pone.0021950.g001
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antibody alone (Figure 1F). In addition, for a demonstration of
selective specificity, the EL were screened using poxvirus-naive
serum (Figure 1G) as well as a poxvirus-naive serum with a high
anti-dengue virus titer (Figure 1H). No positive signals were seen in
the control screenings.
Identification of immunogenic VACV proteins
For the construction of EL, genomic OPV DNA was partially
digested with the Bsp143I restriction enzyme and cloned into the
ZAP Express vector. Through serological screenings immunore-
active phage clones were identified and the insert DNA sequenced.
The DNA sequences obtained were aligned with an appropriate
reference OPV genome for the identification of the encoded
protein(s). For convenience, the genes encoding the identified
immunogenic proteins are indicated according to the established
convention of naming VACV genes or ORFs. This consists of
using the HindIII restriction endonuclease DNA fragment letter
(A-P), followed by the ORF number within the fragment, and L or
R, depending on the direction of the ORF [2]. When inserts
encode more than one protein, no precise identification of the
antigenic protein is possible. In that case, the position of the
identified genomic region is indicated through the respective
HindIII fragment letter.
The constructed genomic EL were screened with anti-OPV sera
to scan the humoral immune response from vaccinated or infected
humans and animals. EL containing the VACV genome were used
to identify immunoreactive proteins of VACV. This should serve
as a proof of principle for the functionality of the EL prior to the
identification of CPXV-reactive proteins. The serological screen-
ing of EL-VACV-3k-12k using sera from immunized humans
(Vaccinia immune globulin, VIG) and rabbits as well as clinical
human sera resulted in the identification of several immunoreac-
tive plaques. After sequencing of the insert DNA, immunodomi-
nant genome regions encoding several proteins could be identified.
One of the most frequently detected genomic regions was in the
HindIII A fragment, which almost always included the gene
WR148, the VACV orthologue of the cowpox A-type inclusion
protein (A25). Proteins encoded by HindIII fragments D and C/B
could also be identified.
The screening of EL-VACV-3k-12k did not result in the precise
attribution of immunoreactive plaques to individual proteins,
owing to the fact that the relatively long inserts often encode more
than one protein. To circumvent this problem, EL-VACV-0.2k-0.7k
was constructed. The serological screening of this EL using rabbit
antiserum resulted in the identification of the immunoreactive
proteins A18 (DNA helicase), A47 (hypothetical protein), B2
(function unknown), and E3 (double-stranded RNA-binding
protein) (Table 1).
Identification of immunogenic CPXV proteins
EL-CPXV-0.2k-0.7k and EL-CPXV-0.2k-3k were serologically
screened to identify immunoreactive proteins of CPXV. A wide
range of immunogenic proteins could be identified by screening
both EL using sera from different species (Table 1). Only those
immunoreactive clones encoding a single protein are included in
Table 1. Immunoreactive clones with inserts encoding multiple
proteins were also identified. These are not listed in Table 1 but
are provided below. Screening of EL-CPXV-0.2k-3k using serum
from a CPXV-infected cat resulted in the identification of
immunoreactive clones encoding two proteins B19/B20 (NCBI
accession numbers: NP_619993/NP_619994). Screening of the
same library using anti-CPXV rat serum led to immunoreactive
clones encoding the protein combinations A41/A42 (NCBI
accession numbers: NP_619960/NP_619961), A43/no homo-
logue (NCBI accession numbers: NP_619962/NP_619963), and
I4/I5 (NCBI accession numbers: NP_619870/NP_619871).
OPV proteins with diverse functions are immunogenic
The first main discovery of our serological screening was that
immunogenic proteins can have most diverse functions. Interest-
ingly, a few enzymes including A18 (DNA helicase), A48
(Thymidylate kinase), E9 (DNA polymerase), and H6 (DNA
topoisomerase type I) were found to be immunogenic. Moreover,
several ankyrin-like proteins (M1, B18, and B20) were found to be
immunoreactive. A number of immune evasion proteins including
A53 (tumor necrosis factor receptor, CrmC), C23 (chemokine-
binding protein), and E3 (double-stranded RNA-binding protein)
were also found to be antigenic. According to their different
functions, the detected immunogenic OPV proteins varied in their
location within the virus, ranging from core proteins (A3, A4) to
membrane proteins (B22), including structural proteins (M1, B18,
B20) as well as enzymes. Interestingly, there was no trend toward
recognition of antigens with early or late gene expression.
Genes encoding immunoreactive proteins are widely
dispersed on an OPV genome
We also analyzed the distribution of the genes encoding
immunoreactive proteins on a generalized OPV genome map
(Figure 2). For simplicity, we again depicted an OPV genome
containing HindIII restriction endonuclease DNA fragment letters
(A-P). HindIII DNA fragments with genes encoding identified
immunoreactive proteins are highlighted with a respective EL-
specific icon. Figure 2 gives a detailed overview of the proportion
of the OPV genome encoding immunogenic proteins. It contains
the identified genes listed in Table 1 as well as the information on
immunoreactive clones with inserts encoding two or more genes.
The immunodominant genes were found to be part of nearly all
different HindIII restriction fragments, including genes located in
the central region of the genome as well as those in the terminal
regions.
VACV and CPXV cross-reactive proteins A4 and E3 are
most antigenic
The constructed VACV and CPXV EL were also utilized to
determine cross-reactive OPV antigens. For this purpose VACV
EL were screened using anti-CPXV sera, and CPXV EL were
screened using anti-VACV sera. To be able to identify cross-
reactive proteins, the identified antigens were grouped into four
subsets depending on the experimental conditions: 1. CPXV EL
with anti-VACV sera, 2. CPXV libraries with anti-CPXV sera, 3.
VACV libraries with anti-VACV sera, and 4. VACV libraries with
anti-CPXV sera (Figure 3). All proteins attributed to subsets 1 and
4 represent cross-reactive antigens of VACV and CPXV.
Moreover, the presence of a protein in more than one subset
indicates a higher antigenicity. By determining the intersections of
all subsets, protein A4 was found to be present in all four subsets.
In addition, protein E3 was present in two of four subsets. We
therefore conclude that out of the 16 proteins identified, A4 and
E3 are the most antigenic cross-reactive proteins between CPXV
and VACV.
Discussion
Beside the discussion of potentially re-emerging VARV
infections, the increasing number of CPXV infections, particularly
in young people [13,30–32], reawakened the interest in this
zoonotic poxviral disease. As a result of discontinued smallpox
Cross-Reactive Orthopoxvirus Antigens
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monkeypox are regarded as emerging zoonotic hazards, requiring
the development of new effective therapies or vaccines [17].
Recombinant subunit vaccines are considered to be safer than
conventional live or attenuated vaccines [25]. Their development
depends on the identification of cross-reactive OPV antigens that
will likewise stimulate the most effective immune response to
infectious virus. Many antigenic proteins of VACV have been
identified as possible candidates in this context [33,34]. However,
genetic diversity between OPVs has not yet been taken into
account [25] nor the fact that, beside VARV, monkeypox virus
and CPXV are actually important pathogenic poxviruses.
In this study a set of 21 different immunogenic proteins could be
identified by serological screening of genomic CPXV and VACV
expression libraries (EL) using anti-VACV and anti-CPXV clinical
sera. The whole set of these identified proteins was subsequently
analyzed to identify cross-reactive OPV antigens.
The method described here allowed the identification of
antibodies specific for OPV proteins. Like every method the
serological screening of genomic l-based EL has its benefits and
limitations. One of the most important benefits is the fact that the
construction of such a library does not require any prior
knowledge of antibody targets. Therefore it is not necessary to
predict ORFs of unknown proteins and to design primers using
software, which allows the identification of new antigens.
Furthermore, genomic EL ideally contain the entire host genome
and express the complete set of virus-encoded proteins. This is
especially advantageous for viruses with a large genome like that of
Table 1. CPXV and VACV antigens identified by screening of genomic expression libraries.
VACV-Cop homolog Gene name Accession numbers EL
a EL
b EL





f AAO89417 x DNA helicase +
A47L WR-173 AAO89452 x Hypothetical protein +
B2R WR-184 AAO89463 x Unknown +
A3L CPXV135
g AAM13576 x P4b precursor +
A25L CPXV158 AAM13600 x x A-type inclusion body protein +
A48R CPXV186 AAM13626 x Thymidylate kinase +
A53R CPXV191 AAM13631 x Tumor necrosis factor receptor
(CrmC)
2
B10R CPXV204 AAM13643 x Kelch-like protein +
B22R CPXV219 AAM13657 x Surface glycoprotein 2
C10L CPXV033 AAM13480 x Hypothetical protein +
C23L CPXV003 AAM76298 x Chemokine-binding protein 2





x x Double-stranded RNA-binding
protein
+
E9L CPXV075 AAM13520 x DNA polymerase +
H6R CPXV115 AAM13558 x DNA Topoisomerase type I +
M1L CPXV039 AAM13486 x Ankyrin-like protein +
Humans
i
D13L CPXV131 AAM13572 x Rifampicin resistance protein +
Cats
j
F12L CPXV060 AAM13505 x IEV-associated protein +
Rats
k












x x x 39 kDa core protein +
aIdentified by serological screen of EL-VACV-0.2k-0.7k.
bIdentified by serological screen of EL-CPXV-0.2k-0.7k.
cIdentified by serological screen of EL-CPXV-0.2k-3k.
dOrthopoxvirus Immune Epitope Database (IEDB) hits (www.immuneepitope.org).
eReactive in immunized rabbits (Lister strain).
fReference genome for alignment VACV strain Western Reserve (GenBank acc. no. AY243312).
gReference genome for alignment CPXV strain Brighton Red (GenBank acc. no. AF482758).
iReactive in immunized humans (VIG).
jReactive in CPXV-infected cats.
kReactive in CPXV-infected rats.
doi:10.1371/journal.pone.0021950.t001
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we have shown that they cover large parts of the viral genome by
sequencing randomly picked clones. Therefore this approach
allows the investigation of the humoral immune response without
prior restriction to a certain protein class. Nevertheless, it is
important to note that the fraction of sequences incorporated in a
recombinant DNA library depends on the degree of partial DNA
digestion [35]. The size of OPV proteins ranges from less than 50
amino acids to more than 1,000 amino acids, implying methodical
problems. On the one hand, it is preferable to identify single OPV
proteins during the screening process by using inserts of even
shorter length. On the other hand, short inserts could result in the
translation of incomplete proteins that lack the proper folding for
obtaining the native immunogenic structure. To circumvent this
and other limitations, EL containing inserts of different size were
constructed. Moreover the serological screening of genomic EL is
not an absolutely quantitative method but rather a qualitative
approach. There is no guarantee that all immunoreactive proteins
will be recognized and identified even when specific antibodies are
present. However, due to the number of clones screened, several
immunogenic proteins should be found. This constriction has been
enhanced by pre-diluting the immune sera from 1/200 to 1/1,000.
This elicited only the discovery of the most antigenic proteins that
could be suitable for inclusion in vaccines.
Antigens expressed in E. coli may not completely parallel those
expressed in OPV-infected eukaryotic cells, due to a lack of post-
translational modifications. Additionally, solid-phase immobiliza-
tion of library-expressed proteins may mask protein epitopes or
affect the three-dimensional structure of the antigens. To assess the
impact of these factors on the ensuing screening experiments, anti-
rA27 antibodies were tested in ELISA assays. The anti-rA27
antibodies were generated in goats and mice immunized with a
recombinant protein expressed in E. coli. The specificity of these
antibodies was tested in ELISA by coating the recombinant
protein as well as VACV particles. The antibodies were shown to
recognize both. Thus, the immobilized recombinant A27 protein
expressed in E. coli and coated onto plastic was still in a
conformation similar to that present on virus particles. The same
antibodies were used for the validation of the EL by an
immunoscreening which resulted in the identification of the
A27L gene. Additionally, the EL were screened with a monoclonal
antibody raised against native CPXV particles. This screenings
also resulted in immunoreactive plaques. Taken together these
results demonstrate that phage-expressed proteins are detected by
antibodies generated against native virus particles as well as by
those raised against proteins expressed in E. coli.
Although a number of immunogenic OPV proteins has been
identified so far, the cross-reactivity of these antigens was not yet
adequately taken into account. Our primary goal was, therefore, to
develop a method for the identification of proteins that are
immunogenic and cross-reactive to different OPVs. For this
purpose, VACV genome-containing EL were screened first with
anti-VACV sera to demonstrate the suitability of the approach
selected. Subsequently, the serological screening of EL containing
VACV genome with anti-CPXV sera and vice versa was adopted to
identify some of the cross-reactive proteins of VACV and CPXV.
Out of 21 identified immunogenic proteins, 16 were found to be
cross-reactive. All 16 cross-reactive proteins could be identified
through the screening combination of the CPXV EL with sera
from VACV-immunized individuals, including an anti-VACV
hyperimmune rabbit serum. Hyperimmunization is a vaccination
method by which the same antigen is repeatedly administered,
leading to boostered immune responses. On the other hand, the
screening of a VACV EL using anti-CPXV clinical serum samples
resulted in the identification of only one protein, A4. The different
Figure 2. Genome-wide distribution of genes encoding immunogenic proteins. Shown is a generalized OPV genome map with HindIII
restriction endonuclease DNA fragment letters (A-P). The icon-selected HindIII fragments encode at least one immunoreactive protein identified
through plaque screening of the respective EL. Multiply-selected fragments encode immunoreactive proteins identified in more than one EL. The
screenings were performed using sera from VACV -immunized and CPXV-infected humans and animals.
doi:10.1371/journal.pone.0021950.g002
Figure 3. Determination of cross-reactive VACV and CPXV
antigens. The main circle represents the entity of identified immuno-
genic OPV proteins. This set of proteins is divided into four subsets
depending on the experimental setting: 1. CPXV EL screened with anti-
VACV sera; 2. CPXV EL screened with anti-CPXV sera; 3. VACV EL screened
with anti-VACV sera; and 4. VACV EL screened with anti-CPXV sera.
Subsets 1 and 4 contain cross-reactive antigens. The inner circles
represent the intersection of identified antigens. Thereby a differentia-
tion is made between the same protein being present in two different
subsets and a protein being present in all four subsets (central circle).
doi:10.1371/journal.pone.0021950.g003
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different screening combinations has various reasons.
First of all, only immunoreactive clones with inserts encoding
single proteins are listed in Table 1 and included in Figure 3.
Thus, the screening results of EL-VACV-3k-12k which contains
longer inserts are not depicted. The screening of EL-CPXV-0.2k-3k
resulted in immunoreactive clones with inserts coding for single as
well as multiple proteins. On the other hand, all clinical serum
samples were obtained after a primary, naturally acquired CPXV
infection. Here it is important to note that the serological screening
of the EL with hyperimmune sera resulted in the identification of
more cross-reactive antigens than a screening with a serum from
naturally infected individuals did. These results perfectly correlate
with the progression of a humoral immune response. Primary
immune responses are often weak due to a limited amount of
presented antigen. Therefore, only B cell clones producing high
affinity antibodies or those with antigen receptor specificities for
the most abundant antigen are selected for proliferation.
Interestingly, A4 was identified as the most abundant protein in
intracellular mature virions of VACV [3]. Following the second
and subsequent boosts to the antigen, the affinity and amount of
antibodies increase due to a process called affinity maturation.
Hence, more antigenic determinants can be identified using
conventional serological techniques. Therefore, clinical sera will
usually be able to recognize fewer proteins than hyperimmune sera
do. Finally, as mentioned above, the serological screening of
genomic EL is not an absolutely quantitative method.
To get a general overview of cross-reactive antigens, it is therefore
advisable to screen EL with sera of immunized or even better
hyperimmunized individuals. Antibodies present in those sera have
higher affinities for their cognate antigen due to somatic hypermuta-
tion. This allows an easier identification of the antibody targets using
serological screening methods. However, screening of EL using sera
obtained after a primary infection can result in the identification of
the most antigenic or the most abundant cross-reactive proteins.
Among the identified cross-reactive proteins A4 was the most
frequently identified immunogen. A4 (p39) was first identified by
Maa and Esteban [36] as a highly antigenic protein eliciting a
strong humoral immune response in rabbits and mice. They could
also demonstrate the protein to be cross-reactive between VACV
and CPXV and therefore supposed that it might have important
biological functions [36]. More recently, DNA plasmids encoding
the A4L gene were used to prime mice before a boost with VACV,
resulting in an improvement of the immune reaction compared to
the current vaccination strategy [23].
The immune evasion protein E3 was the second most frequently
identified cross-reactive protein. E3 is an important virulence gene
responsible for providing interferon resistance. E3 deletion mutants
were shown to be less pathogenic in mice models [37–39], and thus
it was proposed to use them as attenuated vaccines [37].
Among the identified proteins, D13, E3, A3, A4, H6, B2, and
E2 were earlier shown to be immunogenic by using a VACV
proteome microarray approach [34,40]. Sahin and colleagues
showed the proteins A4, A25, E9, F12, B2, and D13 to be
antigenic by screening genomic shot-gun EL [41]. Finally, the
immunogenicity of D13 and A4 was shown in a microELISA
format with proteins derived from a mammalian in vitro expression
system [33]. Thus, 10 out of 21 immunogenic proteins identified
have been described as OPV antigens before. To our knowledge,
the remaining 11 proteins have not been identified before as
antibody targets using genome-wide screening approaches. We
further compared our set of identified immunogenic proteins with
the records of the Immune Epitope Database. This database
provides a compilation of experimentally determined B- and T-cell
epitopes [42]. For nearly all of the identified immunoreactive
proteins, the presence of one or more Immune Epitope Database
hits could be confirmed. However, to our knowledge, vaccinia
homologues A53 (CPXV191), B22 (CPXV219), and C23
(CPXV003) are not yet known to contain any B- or T-cell
epitopes. All of these proteins were also identified as being cross-
reactive between VACV and CPXV. Thus, we were able to
identify three new immunogenic OPV proteins which are cross-
reactive between CPXV and VACV.
The screening of the EL using sera from different species
(rabbits, humans, cats, and rats) resulted in the identification of
two common antibody target proteins. The protein B20 was
detected by antibodies present in VACV-immunized humans and
rabbits. Furthermore, rabbit anti-VACV sera and cat anti-CPXV
sera reacted with the protein A4. These commonly recognized
antibody targets could be particularly well suited for vaccine
design. However, the pooling of screening results for different
species infected with different OPV strains could also result in
conflicting data. It is therefore important to note that the type of
infection and thus the protective immunity mounted against an
OPV infection can depend on multiple factors. These include the
species of OPV, the route of virus entry, as well as the genus/
species of the host and its immune status [1,43]. Furthermore, the
impact of the primary versus secondary immune response to the
obtained antigens should be taken into account [43].
An ideal subunit vaccine should protect against different OPV
species. This could be achieved by including proteins which are
highly conserved among OPV species and are therefore cross-
protective. It has been shown that even slight heterogeneity of
proteins could result in the loss of cross-protection [44,45]. Out of
16 cross-reactive proteins identified, six (A3, A4, D13, E2, E9, and
H6) are perfectly conserved in all members of the subfamily
Chordopoxvirinae [11,46] which also includes the genus OPV.
In summary, we have identified 16 cross-reactive proteins of
CPXV and VACV by serological screening of genomic EL. Six of
these proteins are perfectly conserved among all OPV species.
Furthermore, we have identified three unknown immunogenic
OPV proteins which are also cross-reactive between CPXV and
VACV. Due to their conservation and frequency of detection, we
propose that seven of the cross-reactive antigens identified, namely
A3, A4, D13, E2, E3, E9, and H6, could be considered for
inclusion in subunit vaccines. This could result in protection not
only against CPXV but also against VARV and monkeypox virus.
To our knowledge, only the protein A4 has so far been tested as a
possible subunit vaccine component. The construction and
serological screening of further genomic EL with VARV and
monkeypox virus genomes could reveal more cross-reactive
antigens and speed up the development of safer vaccines.
Materials and Methods
Enzymes
DNA restriction endonuclease Bsp143I and T4 DNA Ligase
were purchased from Fermentas (St. Leon-Rot, Germany).
Bacterial strains
The E. coli strains XL1-Blue MRF’ and XLOLR were
purchased from Agilent Technologies, Inc. (Santa Clara, CA,
USA). The E. coli strain Rosetta
TM was purchased from Novagen
Inc. (Darmstadt, Germany).
OPV strains
VACV strain New York City Board of Health (NYCBH; VR-
1536
TM) Laboratories was purchased from American Type
Cross-Reactive Orthopoxvirus Antigens
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a CPXV-infected elephant infected by a rat [47]. A CPXV named
calpox virus was isolated from New World monkeys [48,49].
Recombinant A27 protein (rA27)
For the expression of A27, viral DNA was isolated from the
calpox virus [48,49]. The A27L gene was PCR amplified in a
50 ml reaction containing 16PCR Buffer (Invitrogen, Darmstadt,
Germany), 4 mM MgCl2, 100 mM dNTPs, 0.3 mM of each primer
(CTgTACTTTCCATggACggAACTCTTTTCC and TTgAgT-
CTgCAgATATggTCgCCgTCCAgT), 1 unit Platinum Taq DNA
polymerase (Invitrogen), and about 50 ng of template DNA. The
cycling was carried out in a MastercyclerH ep gradient (Eppendorf,
Hamburg, Germany) under the following conditions: 94uC for
2 min, followed by 30 cycles of 94uC for 20 sec, 63uC for 20 sec,
and 72uC for 30 sec, and completed by 72uC for 10 min. The
amplicons were purified using Qiaquick PCR purification Kit
(Qiagen GmbH, Hilden, Germany) according to manufacturer’s
instructions. For expression of A27L gene, the purified amplicons
were ligated into the pTriEx-3 vector (Novagen Inc.). The
amplicons as well as the vector were predigested with the
restriction enzymes NcoI and PstI prior to ligation reaction. The
ligated DNA was subsequently used to transform competent E. coli
strain Rosetta
TM cells. The recombinant His-tag protein was
finally purified under denaturing conditions using ProtinoHNi-IDA
columns (Macherey-Nagel, Du ¨ren, Germany).
Sera, monoclonal antibodies, and enzyme conjugates
Vaccinia immune globulin (VIG), which is the immunoglobulin
fraction of pooled vaccinia-hyperimmune human serum, was a
generous gift from BEI Resources (Manassas, VA, USA). The
hyperimmune rabbit anti-VACV (strain Lister) serum was
obtained from Acris Antibodies GmbH (Herford, Germany).
The clinical serum samples included human, cat, and rat sera
collected from CPXV-infected individuals. The human serum was
collected 8–9 weeks post infection, the cat serum 3–4 weeks post
infection, and the rat serum 2–3 weeks post infection. All clinical
material was provided by the German Consultant Laboratory for
Poxvirus infections (Robert Koch Institute, Berlin, Germany).
The human anti-dengue virus serum was collected 2–3 weeks
post infection. To show the absence of anti-OPV antibodies, both
the human anti-dengue virus serum and the human poxvirus-naive
serum were tested by immunofluorescence assay, as described
elsewhere [49]. Briefly, for the detection of OPV-specific
antibodies slides were coated with CPXV GuWi-infected Hep2
cells. For the detection of dengue virus-specific antibodies slides
were coated with dengue virus-infected (dengue virus type 1) Vero
E6 cells (European Collection of Cell Cultures, ECACC:
85020205). The polyclonal goat anti-rA27 serum was generated
by subcutaneously immunizing a goat with approximately 200 mg
of the recombinant A27 protein expressed in E. coli. TiterMaxH
Gold was used as adjuvant. The goat was boosted once
subcutaneously four months later with about 300 mg antigen and
the serum was collected two weeks thereafter.
The monoclonal anti-CPXV 3D11 antibody [29] was kindly
provided by Claus Peter Czerny. The monoclonal mouse anti-
rA27 A1/6-15 was generated using the hybridoma technology by
immunizing C57BL/6 mice with the recombinant A27 protein
expressed in E. coli.
Horseradish peroxidase (HRP)-conjugated goat anti-human
IgG (gamma chain) and peroxidase-rec protein A were purchased
from Invitrogen (Darmstadt, Germany). Goat anti-rabbit IgG-
HRP and Goat anti-mouse IgG Fcc-HRP were obtained from
Jackson Immunoresearch (West Grove, PA, USA). Donkey anti-
goat IgG (H+L)-HRP was purchased from Dianova GmbH
(Hamburg, Germany).
ELISA assays
For ELISA testing of anti-rA27 antibodies 200 ng of rA27 or
5610
6 UV-inactivated VACV particles (strain NYCBH) were
coated over night in 100 ml/well (0.1 M NaHCO3 pH 9.6) of a
96-well MaxiSorp ELISA plate (Nunc, Langenselbold, Germany).
The wells were then blocked with Tris-buffered saline containing
0.05% Tween 20 (TBS-T) and 3% BSA for 1 hr at room
temperature. After four washing steps (300 ml/well TBS-T) the
diluted anti-rA27 antibodies (in TBS-T with 0.25% BSA) were
added at 100 ml/well and incubated for 1 hr at room temperature.
Subsequently, the wells were washed again four times and the
diluted HRP-conjugated goat anti-mouse or donkey anti-goat
antibodies were added (100 ml/well, 1:5,000 diluted in TBS-T
with 0.25% BSA) and incubated for 1 hr at room temperature.
After four further washes, bound HRP was detected using
3,39,5,59-Tetramethylbenzidine (TMB) substrate tablets (Sigma,
St. Louis, MO, USA) and assayed at 450 nm with a reference
measurement at 620 nm (InfiniteH200 PRO microplate reader,
Tecan Group Ltd., Ma ¨nnedorf, Switzerland).
Sera pre-treatment
Sera generally contain antibodies to E. coli proteins, which can
cause a high background signal. To reduce this background signal,
sera were pre-incubated with E. coli (strain XL1-Blue MRF9)
lysate. The lysate was prepared by growing an E. coli culture to
saturation and harvesting the cells by centrifugation (15 min,
1,5006g). The cells were then resuspended in a buffer containing
50 mM Tris-HCl (pH 8.0) and 10 mM EDTA and were
subsequently broken by three successive freeze-thaw cycles,
followed by 361 min sonication steps (Sonifier S-450D, Branson,
Danbury, CT, USA). The cell debris was then removed by
another centrifugation step (15 min, 1,5006g). The resulting lysate
(supernatant) was used for incubation with the diluted serum for
30 min at room temperature.
Ethics statement
The clinical cat and rat sera used to screen the genomic
expression libraries were provided by the German Consultant
Laboratory for Poxvirus infections (Robert Koch Institute, Berlin,
Germany). No specific ethical approval was required, since all sera
were diagnostic material and no animal experiments using
laboratory animals were performed.
Preparation of genomic DNA for cloning
Purification of genomic DNA. OPVs were grown in
175 cm
2 culture flasks containing a monolayer of Hep2 cells
(ATCC) for three days (VACV) or five days (CPXV), respectively.
Approximately 2.7610
7 cells were infected with a virus input
multiplicity of infection (MOI) of 0.25 (VACV) and 0.1 (CPXV),
respectively. The preparation of poxvirus DNA from the cytoplasm
of infected Hep2 cells was performed as described in [50]. The
concentration of the prepared DNA was determined using
NanoDrop 1000 (Thermo Scientific, Wilmington, DE, USA). The
integrity of the genomic DNA was estimated on a 0.5% agarose gel
prepared in 16TAE buffer with 1 mg/ml ethidium bromide.
Real-time PCR. The ratio between poxvirus and human DNA
was estimated by real-time PCR using two different assays. For the
detection of OPV DNA the OPV assay was used. The cellular DNA
wasdetectedby using the c-myc assaywhichdetectsthe housekeeping
gene c-myc. The real-time PCR was performed as described
Cross-Reactive Orthopoxvirus Antigens
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the respective target sequence were measured in each run. For
plasmid construction the corresponding sequences were amplified
and cloned into a TOPO TA vector (Invitrogen, Karlsruhe,
Germany) as described previously [52]. The cycling was carried out
in an Mx3000P QPCR system (Agilent Technologies, Inc.) under the
following conditions: 95uC for 10 min, followed by 40 cycles of 95uC
for 15 sec and 60uC for 30 sec.
Partial digestion of genomic DNA. Partial digestion of
g e n o m i cp o x v i r u sD N Aw a sp e r f o r m e du s i n gt h eD N Ar e s t r i c t i o n
endonuclease Bsp143I (Fermentas). The amount of Bsp143I applied
depended on the DNA insert size desired for cloning. For a fragment
size of 3 kb to 12 kb a BspI concentration of 0.01 U/mgt od i g e s t
about 60 mg of genomic poxvirus DNA was convenient. A fragment
size of 0.2 kb to 3 kb could be achieved by digesting about 50 mg
DNA with 0.15 U/mg of Bsp143I. For a fragment size of 0.2 kb to
0.7 kb, 0.5 U/mg of Bsp143I for about 50 mg DNA was convenient.
Size fractionation. The partially digested poxvirus DNA was
fractionated on agarose gels at 50 V for 2–3 hr. The agarose
concentration depended on the fragment size to be fractionated:
0.5% for 3 kb to 12 kb fragments, 0.8% for 0.2 kb to 3 kb
fragments, and 1.5% for 0.2 kb to 0.7 kb. The fractionated DNA
was visualized under long-wave UV light, and the desired fragment
range was excised using a scalpel. The excised gel slices were
weighed and the DNA extracted using Nucleospin Extract II Kit
(MachereyNagel) according to the manufacturer’s instructions. The
extracted DNA was diluted in 15 ml elution buffer and the DNA
concentration determined using NanoDrop 1000.
Construction of OPV expression libraries
Starting from ligation reaction, all genomic ELs were
constructed using the ‘‘ZAP ExpressH Predigested GigapackH III
Gold Cloning Kit’’ (purchased from Stratagene, La Jolla, CA,
USA, now Agilent Technologies, Inc.) with the BamHI/CIAP-
treated vector (former catalog #239615, currently not available)
according to manufacturer’s instructions. Methods for which
modifications to the original protocol or amount specifications of
reagents were necessary are described below.
The partial digestion of DNA with Bsp143I enzyme results in
DNA ends compatible with those produced by the restriction
enzyme BamHI. Thus, the partially digested genomic OPV DNA
was directly ligated into the BamHI-predigested ZAP Express
vector without modifying the DNA ends. The following DNA
amounts were ligated for each EL: 336 ng for EL-VACV-3k-12k,
185 ng for EL-VACV-0.2k-0.7k, 80 ng for EL-CPXV-0.2k-0.7k, and
36 ng for EL-CPXV-0.2k-3k in a final volume of 7 ml. DNA from
ligation reactions was directly used for the packaging reactions.
The following volumes of ligation reaction were used for
packaging: 3.5 ml for EL-VACV-3k-12k,4ml for EL-VACV-0.2k-
0.7k and EL-CPXV-0.2k-0.7k, and 7 ml for EL-CPXV-0.2k-3k.
Validation of OPV expression libraries
For an assessment of their quality all four EL constructed were
extensively validated. Hereby, the representativeness of the EL was
assessed by randomly picking 25–60 recombinant plaques from
every library and by sequencing the DNA inserts. The obtained
sequences were aligned to a reference poxvirus genome to estimate
the distribution of the sequences. Additionally, all four EL were
serologically screened using monoclonal (anti-rA27 A1/6-15 anti-
CPXV 3D11) and polyclonal (goat anti-rA27) antibodies.
Plaque immunoscreening of OPV expression libraries
All four constructed OPV EL were screened with selected
polyclonal and monoclonal antibodies. The plaque-screening
procedure was performed as described in the picoBlue
TM
Immunoscreening Kit (Agilent Technologies, Inc.) with minor
changes. Briefly, 150 mm dishes with phage plaques growing for
4h ra t4 2 uC on a lawn of E. coli XL-1 Blue MRF9 cells in 0.7%
soft agar were overlaid with nitrocellulose filter disks (PALL
Gelman Laboratory, Ann Arbor, MI, USA) presoaked in 10 mM
isopropyl-b-thiogalactoside (IPTG). After incubation for 4 hr at
37uC, the filters were removed, washed in TBS-T at room
temperature, and blocked in Tris-buffered saline (TBS) containing
1% bovine serum albumin. Filters were then incubated in
succession with monoclonal antibodies/sera and HRP-conjugated
secondary antibodies, with 3–5 TBS-T washes between every
incubation step. The monoclonal antibodies were diluted to
0.5 mg/ml in TBS with 1% BSA. The sera VIG, rabbit anti-
VACV, cat anti-CPXV, and goat anti-rA27 were diluted 1:1,000.
Rat anti-CPXV serum was diluted 1:200. The binding of HRP-
conjugated antibodies was detected through the color develop-
ment reaction with the substrate 3-Amino-9-ethylcarbazole (AEC,
Sigma). Immunopositive plaques resulted in small reddish dots on
the membrane. This membrane was then aligned with the original
agar plate, allowing identification of corresponding plaques. After
staining, positive plaques were picked, suspended in buffer, and
plaque-purified once on 90 mm dishes. For this, phage solutions
were diluted (10
21–10
23), plated, and incubated over night at
37uC. The plates were again overlaid with nitrocellulose
membranes (PALL Gelman Laboratory), incubated for 4 hr at
37uC, and stained. Positive plaques were picked again (without
adding chloroform to buffer), and the contained pBK-CMV
phagemid vector was excised in vivo as described in the ‘‘ZAP
ExpressH Predigested GigapackH III Gold Cloning Kit’’ (Agilent
Technologies, Inc.) instruction manual. From the bacterial
colonies appearing on the agar plates the excised pBK-CMV
double-stranded phagemid vectors were isolated using NucleoS-
pinH Plasmid QuickPure Kit (Macherey-Nagel) according to the
manufacturer’s instructions and the DNA amount quantified using
the NanoDrop1000.
PCR and DNA sequencing
The isolated pBK-CMV phagemid vectors were used as
templates for PCR. For the amplification of long inserts ($3 kb)
the ‘‘Expand Long Range, dNTPack’’ (Roche Diagnostics GmbH,
Mannheim, Germany) was used according to the manufacturer’s
instructions as a 25 ml reaction containing 3% DMSO. The
amplification of shorter fragments was performed as a 25 ml
reaction containing 16PCR Buffer (Invitrogen), 4 mM MgCl2,
100 mM dNTPs, 0.3 mM of each primer (T7 primer: gTAATAC-
gACTCACTATAgggCg and T3 primer: ATTAACCCTCAC-
TAAAgggA), 1 unit of Platinum Taq DNA polymerase (Invitro-
gen), and about 50 ng of template DNA. The cycling was carried
out in a Mastercycler ep gradient (Eppendorf) under the following
conditions: 95uC for 5 min, followed by 40 cycles of 95uC for 30 s,
57uC for 30 s, and 72uC for 60 s, completed by 72uC for 5 min,
and cooling down to 4uC until further processing. The amplified
DNA inserts were cycle sequenced using the flanking primers T3
and T7 and the BigDyeH Terminators chemistry (Applied
Biosystems, Weiterstadt, Germany).
Data processing
The obtained sequences were aligned to VACV strain Western
Reserve (WR) genome (GenBank acc. no. AY243312.1) for
VACV genome-containing EL and to CPXV strain Brighton
Red (GenBank acc. no. AF482758) for CPXV libraries. The
alignment was performed using the BLASTN program by
optimizing for highly similar sequences (megablast).
Cross-Reactive Orthopoxvirus Antigens
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Figure S1 Validation of constructed genomic OPV
expression libraries. Recombinant plaques were picked, the
insert DNA sequenced and the obtained sequence aligned to a
reference genome. Shown is the distribution of DNA-inserts
obtained from recombinant clones from (A) EL-VACV-3k-12k
displayed on a VACV genome (GenBank AY243312.1), and (B)
EL-CPXV-0.2k-0.7k displayed on a CPXV genome (GenBank
AF482758.2). The graphics were created using the nucleotide
database on the NCBI website (http://www.ncbi.nlm.nih.gov/
nuccore). By choosing the appropriate reference genome and the
display setting ‘‘graphics’’, the DNA inserts from recombinant
clones could be defined as markers. Each DNA insert obtained
from a recombinant clone is represented by a dot and the
respective color-shaded bar. These colored bars indicate the size of
the DNA insert and the covered genes. The pairs of horizontal
green and red bars represent annotated genes on the dsDNA
poxvirus genome.
(TIF)
Figure S2 Screening of an expression library with an
anti-CPXV antibody. For a validation of their complexity the
constructed genomic EL were serologically screened with the
monoclonal antibody 3D11 that was raised against native CPXV
particles. Immunopositive signals are exemplary indicated through
white arrows on a stained nitrocellulose filter obtained through
screening of EL-VACV-3k-12k.
(TIF)
Figure S3 Validation of anti-rA27 antibody reactivity in
ELISA. Polyclonal goat anti-rA27 and monoclonal mouse anti-
rA27 were generated by immunizing with a recombinant A27
protein expressed in E. coli. The target reactivities of these
antibodies were tested in an ELISA by coating the recombinant
antigen and whole VACV particles onto ELISA plates and
incubating with serially diluted antibodies: (A) Goat anti-rA27
serum, (B) Mouse anti-rA27 monoclonal antibody.
(TIF)
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